Your browser doesn't support javascript.
loading
Kinases Controlling Stability of the Oncogenic MYCN Protein.
Smith, Nailah; Reznik, Eduard; Bisikirska, Brygida; Polychronidou, Vasiliki; Wang, Qian; Zask, Arie; Forouhar, Farhad; Califano, Andrea; Stockwell, Brent R.
Afiliação
  • Smith N; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
  • Reznik E; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
  • Bisikirska B; Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York City, New York 10032, United States.
  • Polychronidou V; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
  • Wang Q; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
  • Zask A; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
  • Forouhar F; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
  • Califano A; Department of Systems Biology, Columbia University Medical Center, New York City, New York 10032, United States.
  • Stockwell BR; Department of Biological Sciences, Columbia University, New York City, New York 10027, United States.
ACS Med Chem Lett ; 14(12): 1664-1672, 2023 Dec 14.
Article em En | MEDLINE | ID: mdl-38116412
ABSTRACT
We previously identified the natural products isopomiferin and pomiferin as powerful, indirect MYCN-ablating agents. In this work, we expand on their mechanism of action and find that casein kinase 2 (CK2), phosphoinositide 3-kinase (PI3K), checkpoint kinase 1 (CHK1) and serine/threonine protein kinase 38-like (STK38L), as well as STK38, work synchronously to create a field effect that maintains MYCN stability. By systematically inhibiting these kinases, we degraded MYCN and induced cell death. Additionally, we synthesized and tested several simpler and more cost-effective pomiferin analogues, which successfully emulated the compound's MYCN ablating activity. Our work identified and characterized key kinases that can be targeted to interfere with the stability of the MYCN protein in NBL cells, demonstrating the efficacy of an indirect approach to targeting "undruggable" cancer drivers.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos